Olema Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Olema Pharmaceuticals, Inc. (OLMA) on May 21, 2026. The filing discloses the announcement of preliminary clinical data from a Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data was presented in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or operational financial metrics.
Material Changes and Clinical Findings
The primary material event is the release of Phase 1 data for OP-3136 as of a March 2, 2026 data cut-off. Key findings include:
- Safety and Tolerability: The drug was well-tolerated with no dose-limiting toxicities up to 45 mg daily. No Grade 4 or 5 treatment-related adverse events (TRAEs) were observed. The most common TRAEs were dysgeusia (81%), anemia (38%), and neutropenia (34%). No patients discontinued treatment due to TRAEs.
- Efficacy: Among 19 response-evaluable patients, tumor shrinkage was observed in 13 patients. Partial responses were noted in 3 patients (2 confirmed, 1 unconfirmed). The longest duration of treatment was 62 weeks, with 11 patients remaining on treatment.
- Target Engagement: The study demonstrated rapid and sustained reduction in histone H3 lysine 23 levels, confirming on-target KAT6 inhibition.
- Pharmacokinetics: Plasma exposure was dose-proportional, with steady-state concentrations exceeding preclinical efficacy targets at doses of 6 mg and above.
Guidance, Outlook, and Risks
The Company plans to present these data in a poster at the American Society of Clinical Oncology Annual Meeting on May 30, 2026. Additionally, a trial-in-progress poster for the Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib will be presented. The filing includes standard forward-looking statements regarding the potential efficacy and development of OP-3136, noting that actual results may differ materially due to risks discussed in the Company's Form 10-Q for the quarter ended March 31, 2026.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed patient demographics and specific response rates by tumor type.
- Review the upcoming poster presentation at the ASCO Annual Meeting on May 30, 2026, for updated data or additional analysis.
- Examine the Company's most recent Form 10-Q (ended March 31, 2026) for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor the status of the Phase 3 OPERA-02 trial for palazestrant mentioned in the outlook.